Evidence map›Paper›PMID 35011729›Full record

ArticleCells2022

Engineered Liposomes Protect Immortalized Immune Cells from Cytolysins Secreted by Group A and Group G Streptococci.

Hervé Besançon, Yu Larpin, Viktoria S Babiychuk, René Köffel, Eduard B Babiychuk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Liposomal Nanotraps NeutralizeInfectious microbes & diseases · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hervé BesançonInstitute of Anatomy, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-1426-1901
Yu LarpinInstitute of Anatomy, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.
Viktoria S BabiychukInstitute of Anatomy, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.
René KöffelInstitute of Anatomy, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0001-9477-4282
Eduard B BabiychukInstitute of Anatomy, Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.
University of Bern · CH

Funding

Novartis Foundation 16B100
6 · The paper itself

Abstract

The increasing antibiotic resistance of bacterial pathogens fosters the development of alternative, non-antibiotic treatments. Antivirulence therapy, which is neither bacteriostatic nor bactericidal, acts by depriving bacterial pathogens of their virulence factors. To establish a successful infection, many bacterial pathogens secrete exotoxins/cytolysins that perforate the host cell plasma membrane. Recently developed liposomal nanotraps, mimicking the outer layer of the targeted cell membranes, serve as decoys for exotoxins, thus diverting them from attacking host cells. In this study, we develop a liposomal nanotrap formulation that is capable of protecting immortalized immune cells from the whole palette of cytolysins secreted by

Indexed as

Cell DeathCell LineCell Line, TransformedCholesterolCytotoxinsHumansLeukocytesLiposomesNeutralization TestsStreptococcusStreptococcus pyogenesCholesterolCytotoxinsLiposomesantibiotic resistanceantivirulencebacterial infectionimmune cellsliposomenanotrapStreptococcustoxin

Identifiers

PMID35011729
PMCPMC8749993
OpenAlexW4206329178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.